PP01.48: Therapeutic Strategies and Immunotherapy Rechallenge Sensitivity After Progression Following Chemoradiation and Consolidation Durvalumab in Unresectable Stage III NSCLC: The POST-PACIFIC Study

作者：Valentina Santo, Nikhil Mankuzhy, Kristi Beshiri, Lingzhi Hong, Emanuele C. Mingo, Sagal Pannu, Federica Pecci, Edoardo Garbo, J. Alessi, Eleonora Gariazzo, Leonardo Brunetti, Ayesha Aijaz, Elyse Lopez, Samuel Black, Jamie E. Chaft, Adam J. Schoenfeld, Lynette M. Sholl, Abdul Rafeh Naqash, Alessio Cortellini, N. Vokes, Mihaela Aldea, Narek Shaverdian, Biagio Ricciuti · 发表于：Journal of Thoracic Oncology · 年份：2026 · DOI：10.1016/j.jtho.2026.104046 · 研究领域：Cancer Immunotherapy and Biomarkers、Inflammatory Biomarkers in Disease Prognosis、Lung Cancer Research Studies